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Summary 
Background: 
Non-melanoma skin cancers (NMSC) are the commonest cancers worldwide and 
their incidence continues to rise in Australia.(1) Basal cell carcinomas (BCC) form 
the majority of NMSCs, and in the last decade noninvasive therapies have 
significantly reduced excision rates. (1-3)  Non-invasive techniques are increasingly 
important for the diagnosis of superficial BCC which can be safely treated topically.  
Optical coherence tomography has previously been used to diagnose BCC. (4, 5) 
The aim of this study was to investigate the diagnostic accuracy of optical coherence 
tomography (OCT) in the diagnosis of superficial subtype of BCC in a clinical setting.  
 
Methods: 
Lesions which were suspicious for superficial BCC were consecutively recruited into 
this prospective study. The degree of clinical confidence of the diagnosis based on 
clinical and dermoscopic assessments was recorded. Clinical and dermoscopic 
images were taken. OCT images of lesions and adjacent normal skin were acquired 
at baseline visit. A 2mm punch biopsy of the lesion was taken. Interpretation of the 
OCT images were performed by an investigator blinded to the biopsy results. The 
presence of individual OCT features, the OCT diagnosis, and the confidence of this 
diagnosis were recorded. 
 
Sensitivity, specificity, positive predictive value, and negative predictive value for 
each OCT diagnosis were calculated compared with histopathologic diagnosis.  
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Assuming all recruited lesions would be biopsied in routine clinical practice and that 
OCT interpreter confidence had to be ≥90% (high) to diagnose sBCC without a 
biopsy, different clinical scenarios were analysed to detect the diagnostic accuracy of 
OCT and its potential effect on biopsy rates and misdiagnosis rates. Specifically, we 
analysed the following scenarios: 
1) Clinician confidence was high but OCT confidence variable for sBCC 
2) Clinician confidence variable but OCT confidence high for sBCC 
3) Clinician and OCT confidence were both high for sBCC 
 
Tumour depths determined by OCT and biopsy were compared using the Pearson 
correlation test. A test set of these images, made up of the first 71 consecutive 
lesions recruited, was used to test for interrater reliability. These images were 
separately analysed by two other investigators, of varying OCT experience, blinded 
to the biopsy report.  
 
Interobserver agreement between the 3 observers for the OCT-based diagnosis as 
well as the individual OCT features were estimated using Cohen kappa statistics. 
Univariate and multivariate logistic regression were carried out for the OCT features 
and presented as receiver operative characteristic curves. 
 
Results: 
103 consecutive patients with 168 sBCC-like lesions were recruited. 52% were 
sBCC, 26% were other BCC and the remaining was made up of actinic keratosis 
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(AK) or squamous cell carcinoma in-situ (SCCIS), other benign inflammatory 
processes, and two other malignant lesions, namely an amelanotic melanoma and a 
minimally invasive squamous cell carcinoma (SCC). 
 
Sensitivity, specificity, PPV (positive predictive value) and NPV (negative predictive 
value) of OCT in the diagnosis of sBCC was 0.87, 0.80, 0.83 and 0.86, respectively.  
 
Different clinical scenarios were analysed and showed that OCT had the potential to 
reduce biopsy rates. OCT can be used in situations where clinical confidence of 
sBCC is: 
- variable as it would reduce biopsy rate by 40% with the risk of misdiagnosing 
3 other BCC cases (4%) and 
- high (≥90%) as it would reduce biopsy rate by 76% with the risk of 
misdiagnosing 2 other BCC cases (5%) 
 
There was excellent correlation amongst tumours <0.4mm (Pearson’s correlation 
r=0.86, p<0.001) but correlation was less as depth increased. (Pearson’s correlation 
r=0.71, p<0.001 for all tumours <1.0mm) 
 
Inter-rater agreement was good between experienced observers (kappa=0.766), and 
fair amongst all 3 observers (kappa=0.596) 
 
A flow chart of the most important features for the diagnosis of sBCC was produced.  
 
Limitations of this study are discussed. 
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 Conclusion: 
OCT is a reliable tool for differentiating between sBCC and other clinical mimickers. 
Clefting, hyporeflective ovoid structures and the absence of a fully encompassing 
cleft are the strongest predictors for a diagnosis of sBCC. Amongst experienced 
users, there is good interobserver agreement for these features and for the diagnosis 
of BCC. In terms of depth measurement, OCT is accurate in tumours under 0.4mm, 
which is useful in determining the type of treatment for sBCC as previous research 
has shown that in these thin tumours, there is zero recurrence rate at a mean follow 
up of 34 months even with topical (imiquimod) treatment.(6) 
 
OCT has the potential to reduce biopsy rates as it is able to diagnose sBCC with a 
high user confidence in clinical scenarios where clinician confidence is variable, 
avoiding biopsy in these cases. When clinician confidence is high, OCT can also 
increase diagnostic accuracy as a proportion of cases are still misdiagnosed by 
clinical examination. However, adequate follow up is required in cases where biopsy 
was not undertaken due to a high OCT confidence as there is a small risk (5%) of 
misdiagnosis. As a result, all lesions not biopsied on OCT examination should be 
carefully examined at follow up and biopsy should be performed if there is any doubt 
on clinical or OCT examination. Amelanotic melanoma may be an important pitfall in 
this technology and caution is recommended in cases of uncertainty. Research is 
ongoing to elicit features differentiating melanocytic and non-melanocytic lesions. 
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 List of abbreviations 
Phrase Abbreviation 
Actinic keratosis AK 
Area under the curve AUC 
Basal cell carcinoma BCC 
Confidence interval CI 
Dermal-epidermal junction DEJ 
Fluorescence confocal microscopy FCM 
Full-field optical coherence tomography FF-OCT 
Haemotoxylin and eosin H&E 
High-definition optical coherence tomography HD-OCT 
High frequency ultrasound HFU 
Harmonic generation microscopy HGM 
Infiltrative BCC iBCC 
Melanoma Institute Australia MIA 
Negative predictive value NPV 
Nodular BCC nBCC 
Non-melanoma skin cancer NMSC 
Odds ratio OR 
Other BCC oBCC 
Optical coherence tomography OCT 
Positive predictive value PPV 
Receiver operating characteristic ROC 
Reflectance confocal microscopy RCM 
Seborrheic keratosis SK 
Superficial BCC sBCC 
Squamous cell carcinoma SCC 
Squamous cell carcinoma in-situ SCCIS 
Ultraviolet UV 
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Introduction 
Background 
Epidemiology of basal cell carcinoma 
Non-melanoma skin cancer (NMSC) consisting of basal cell carcinoma (BCC) and  
squamous cell carcinoma (SCC), is the most prevalent malignancy in Caucasian 
populations.  
 
BCC is the most prevalent cancer in Australia and incidence continues to rise at 
about 3-10% annually.(6)  BCC incidence for older Australians (>60 years old) 
continue to increase whereas it appears to have stabilised in younger Australians – 
this diverging trend being partially attributable to population-based skin cancer 
prevention strategies in Australia since 1980s.(1, 2) Risk factors for BCC include UV 
radiation including sun exposure or therapeutic UV exposure, the use of tanning 
beds, ionizing radiation and long term immunosuppression.(7) 
 
Although BCC is usually not life-threatening, it represents a huge public health 
burden in Australia. The incidence of treated NMSC is more than five times the 
combined incidence of all other cancers, making them the most expensive cancers 
to treat.(8) 
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Basal cell carcinoma and subtypes - clinical, dermoscopy, 
pathology classification 
There is no fixed classification system of BCC and more than 26 histopathologic 
subtypes exists as described by Wade and Ackerman in 1978.(7) Histologic 
examination is typically carried out using Haemotoxylin and Eosin staining (H&E). 
There are four major subtypes clinically and pathologically, namely nodular, 
superficial, morpheaform and fibroepithelial. Combinations of BCC subtypes can 
occur and degree of ulceration and pigmentation can vary. (6, 7) Nodular types tend 
to ulcerate most frequently and majority of BCC are non-pigmented. (7) In general, 
symptoms are rare although stinging, burning or shooting pain raises the possibility 
of perineural invasion.(9) Systematic spread is also extremely rare with incidence of 
0.5% or less.(6)    
 
Clinical  
Nodular BCC 
Of the BCC subtypes, nodular is the most common and accounts for approximately 
50% of all BCCs.(7, 9) Typically, a shiny pearly papule or nodule is seen, with a 
smooth surface and arborizing blood vessels. Over time, the tumour can evolve to 
become bigger and ulcerated, with elevated rolled edges. Nodular BCCs occurs on 
sun-damaged skin, favouring the face especially the cheeks, nasolabial folds, 
forehead and eyelids. Nodular BCC can occur in any skin with hair follicles and are 
rare in the absence of hair follicles. (7, 9) 
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 Superficial BCC 
Superficial BCCs (sBCC) usually present as an erythematous macule or patch, or a 
thin papule or plaque, which is well circumscribed. (6, 7, 9) Additionally, focal scale 
or crusting can occur and a thin rolled border is sometimes seen. Size is variable 
from a few millimetres to several centimetres and in the larger lesions, regression 
can occur spontaneously, characterised by atrophy and loss of pigmentation. It 
preferentially affects the trunk and limbs but are seen also in the head and neck 
region. (7, 9) 
 
 
Morpheaform/Infiltrative BCC 
Morpheaform BCC is less common and typically has a scar-like appearance, similar 
to the plaque of morphea. (7, 9)The affected area is frequently slightly elevated but 
can be depressed and indurated. The colour is usually light pink or white, the surface 
smooth and the borders poorly defined. Crusting, erosions, ulcerations, or 
superimposed papules can be seen. 
 
Fibroepithelial BCC 
Also known as a fibroepithelioma of Pinkus, this is a rare variant of BCC which 
typically presents as a flesh-coloured or pink sessile plaque or pedunculated 
papulonodule with a smooth surface.(7) It tends to occur on the trunk and individuals 
with multiple superficial BCCs are predisposed.(7) 
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 Histology  
Nodular 
Histologically, the tumours are seen as aggregates of basophilic staining cells with 
well-defined contours. Peripheral or palisading and retraction from the surrounding 
stroma is seen. Central necrosis with granular, eosinophilia is a feature of larger 
tumours, surrounding stroma tends to be myxoid in nature.(9) Mitotic activity, 
keratinocyte dyskeratosis, and calcification are thought to be features of more 
aggressive lesions.(9) 
 
Superficial 
Superficial BCC appears histologically as basaloid lobules abutting from the lower 
margin of the epidermis. (7, 9) Although the lobules usually connect in a net-like 
pattern, they appear as “multifocal” lesions at a given two-dimensional plane. (7)  
 
Morpheaform/Infiltrative 
This subtype is consists basaloid cells organised in a pattern of strands or cords 
between collagen bundles. (7) The tumour islands may be small and may be 
perineural so perineural spread is not infrequent. Surrounding stroma is dense – this 
gives rise to the indurated appearance of morphea. (7)  
 
Fibroepithelial  
Histologically, the tumour is characterised by basaloid epithelial strands originating 
from the epidermis, compartmentalising the fibrous stroma. Cyst formation and 
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primitive hair germ maturation may also be present and rarely, a more invasive BCC 
can form within this tumour.(9)  
 
In addition to the subtypes above, pathology yields two further distinct subtypes, 
namely micronodular and basosquamous BCC (9)  As suggested by their names, 
micronodular BCCs made up of smaller aggregates of basaloid cells similar to 
nodular BCC but smaller. (9) It is considered more aggressive with more subclinical 
spread, and more likelihood of recurrence. Clinically, they can present like nodular 
BCC. Similarly, basosquamous BCCs are histologically aggressive, with higher rates 
of recurrence and metastasis, with an incidence of metastasis estimated to be 
greater than 5%.(7) 
 
Regardless of subtype, BCC can contain melanin pigment, leading to the term 
“pigmented BCC”. Histologically, pigmented BCCs contain melanin in melanophages 
or occasionally freely, in the dermis. Nodular, micronodular, and superficial BCC can 
be pigmented but there was no evidence of pigmentation in infiltrative or morphoeic 
BCC. 
 
Dermoscopy 
Dermoscopy is a handheld device with an incident light source and a magnifying 
glass (generally x10), using oil at the skin-microscope interface.  
 
Features of BCC on dermoscopy have been previously described (10, 11). A 
dermoscopy diagnostic method for pigmented BCC has previously been described 
by Menzies et al. For a pigmented BCC to be diagnosed, it should meet the negative 
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feature of not having a pigment network and also have at least one of the six positive 
features of BCC – ulceration, large blue-gray ovoid nests, multiple blue gray 
globules, maple leaf-like areas, spoke wheel areas, arborizing (tree-like) 
telangiectasia. This method has a sensitivity of 97% for diagnosis of pigmented BCC 
and a specificity of 85% for invasive melanomas. (11)  With variably pigmented 
BCCs, the use of dermoscopy has also been proven to diagnose BCC with a high 
level of accuracy (sensitivity of 97%) and reliability (kappa coefficient of 87%). (10)  
Going one step further, recent researchers have tried to correlate the various 
features with different BCC subtypes.(12-15) Arborizing telangiectasias were more 
frequent in nodular BCC whilst in sBCC, short fine telangiectasias were more 
characteristic.(12) Leaf-like areas, spoke wheel areas, small erosions and concentric 
structures were also significantly associated with sBCC.(12, 13) Using dermoscopy, 
sBCC and nodular BCC could be differentiated using dermoscopy but this distinction 
could not be made with other BCC subtypes.(13) A flow chart for dermoscopic 
diagnosis of sBCC (Fig. 1) has been published recently.(13) Based on this model, 
sBCC could be predicted with a sensitivity of 81.9% and a specificity of 81.8%.(13) 
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 Figure 1: Flow chart for diagnosis of sBCC on dermoscopy(13) 
 
Diagnosis of basal cell carcinoma subtype and consequence on 
management 
In BCC diagnosis, incisional biopsy is indicated in all cases especially where 
diagnosis is not clear-cut or when referrals to other subspecialties are anticipated. 
(16) Specifically, the Australian guidelines indicate that biopsy should be done prior 
to treatment due to the need to correctly identify amelanotic melanoma.(8) 
 
Treatment guidelines are not strictly based on evidence but on consensus and 
current guidelines classify lesions to “low risk” and “high risk” depending on the 
histologic subtype.(8, 16) To properly assign the risk status of lesions a biopsy of the 
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lesion is required where information on the histopathologic subtype, presence of 
ulceration, and perineural involvement can be obtained.(16) High-risk subtypes 
include micronodular, infiltrating or morphoeic forms. (8)  
 
Treatment of BCC depends on various factors. Besides the subtype which divides 
them into high risk and low risk, other factors are often taken into consideration, 
including previous history of the patient, the current clinical presentation, the location 
of the lesion and whether any previous treatments have been tried. (8) 
 
Specialist referral is recommended for the treatment of not only high risk subtypes 
but also high risk locations such as central face, ears, genitalia, digits, hand or leg. 
Similarly, recurrent lesions, previously incompletely excised lesions and lesions 
which size is greater than 10mm on the face or scalp or greater than 20mm on the 
trunk and extremities should be managed in a specialist setting.(8) Radiotherapy is a 
form of treatment reserved for a minority of cases where there are contraindications 
to surgery or if the BCC is persistent, recurrent or advanced in which case 
radiotherapy can be used as an adjunct to surgery.(8)  
 
Incompletely excised tumours have a 30% recurrence rate, and this risk of 
recurrence is highest when both the lateral and deep margins are involved.(8) The 
completeness of excision is the most important factor which determines rate of cure 
and recurrence and current recommendations are in the range of 2-5mm excision 
width from the tumour margin. As many as one-third of excised BCCs can have 
close or involved margins, alluding to the difficulty in assessing the tumour margins 
accurately based on clinical examination. This creates an important role for the 
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development of imaging techniques which can assist in accurately determining 
tumour margins so as to prevent recurrence. 
 
Of the BCCs, the superficial subtype is the only one in the low risk category. 
Consequently only sBCC is suitable for non-invasive treatment for which options 
include cryotherapy, photodynamic therapy, medical treatment with imiquimod, 5-
fluorouracil, topical and curettage and cautery.(8, 16)  Surgery and radiotherapy can 
be also be used in sBCC with low failure rates but are more invasive.(16) Invasive 
methods seem unnecessary in low risk lesions since cryosurgery has been proven to 
have a high cure rate.(8, 16) A recent epidemiologic study found that nonsurgical 
treatment of skin cancer is increasing whilst excision rates are on the decline in the 
younger population (<45 years old) in Australia. (1) Imiquimod has also been shown 
to have a zero recurrence rate when used on sBCC < 0.4mm in a mean follow up 
period of 34 months. (17) Given the efficacy and growing popularity of non-invasive 
treatment, biopsy can be viewed as invasive and non-invasive diagnosis becomes 
increasingly relevant.  
 
Although most BCCs can be adequately treated with the methods described above, 
occasionally, some rare cases can progress to a locally-advanced stage where it is 
not amenable to surgery or radiotherapy. Even less common are lesions which 
spread to distant sites, causing additional morbidity and mortality. In these rare 
cases, studies are ongoing but visdodegib, a smoothened homologue inhibitor which 
acts along the hedgehog signalling pathway typically aberrant in BCC, has shown 
promising results in a phase 2 study.(18) 
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Interestingly, a recent phase 3 randomised controlled trial has also demonstrated the 
benefit of nicotinamide in the prevention of BCC and other NMSC. (19) 
 
Non-invasive tools in diagnosis of basal cell carcinoma 
There has been rapid development of diagnostic tools in the field of skin, and 
particularly skin cancers as it provides several advantages to the gold standard of 
histopathology in general. Their non-invasive nature allows visualisation of structures 
without potential harm (e.g. allergy to local anaesthetic) or pain (e.g. to needles). 
These images are available in real-time, offering clinicians and patients a quicker 
result and peace of mind if a benign lesion can be confirmed. Unlike histopathology, 
running costs of these technologies are low, and in the long run can represent cost 
savings. A review of the landscape of diagnostic tools in melanoma, a lethal form of 
skin cancer, was performed and findings are presented in the form of a poster at a 
national melanoma conference in Perth, Western Australia. (Appendix 1)  
 
Diagnostics tools used in BCC are presented below, separately. 
 
In vivo imaging techniques 
Reflectance confocal microscopy (RCM) 
RCM is an imaging tool that is able to achieve “optical biopsy” with a near histologic 
resolution in the upper layers of the skin. Various studies have been published and 
point towards its usefulness in the diagnosis of BCC. (20-24) In a two-step algorithm, 
a high sensitivity of 100% and specificity of 88.5% for the diagnosis of BCC was 
achieved blindly to dermoscopy data.(24) 
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Traditionally, the use of RCM was difficult in challenging areas such as the periorbital 
skin due to its bulky probe. However, a commercially available RCM machine with a 
handheld microscope (Vivascope 3000, Caliber ID, Rochester, NY) has already been 
proven useful in the in vivo diagnosis of tumours in the eyelid margin. (25) With a 
high sensitivity and specificity of 100% and 60%, respectively for BCCs, it is 
particularly useful in avoiding excision of benign lesions. (25) 
 
Similar to histologic confirmation of margins in surgical excision of BCCs, RCM has 
been shown in a small case series to have potential in confirming treatment efficacy 
of laser ablation and MAL-PDT treatment of BCCs.(26, 27) 
 
 
 
 
High frequency ultrasound 
The use of ultrasound in diagnosis of BCC requires the use of high-resolution 
equipment with high-frequency probes in the range of 20-100 MHz.(28). Frequencies 
of 20 to 25 MHz reaches a depth of roughly 7mm, allowing visualisation of the 
epidermis and dermis whereas at 50-100 MHz, resolution increases but depth is 
more limited to 0.15 mm to 3 mm. (29)Images are obtained in the vertical section 
and doppler ultrasound scans can provide additional information about the 
vascularity of a lesion, including the direction and volume of blood flow Three D-
reconstruction is also possible.(30) It is particularly useful in visualising the depth of 
lesions due to its relatively high penetrance with a reported intraclass correlation 
analysis of 0.9 compared to histologic analysis (intraclass correlation coefficient 
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values > or = to 0.9 are very good). (31) However, on the whole, there is no 
consensus regarding use of HFU in delineating surgical margins in NMSCs.(16, 29, 
32-34)  
 
A commonly used system is the 20 MHz scanner (DermaScan Ver. C 3.1; Cortex 
Technology, Hadsund, Denmark), which has an axial resolution of 50 µm, lateral 
resolution of 350 µm (35, 36). Comparing this technology with conventional OCT 
(axial resolution 8 µm, lateral resolution 24 µm, and maximum depth of 2-2.5mm), a 
study of 34 lesions (23 BCC, 11 AK) found that although both methods 
overestimated tumour thickness, OCT was significantly more precise than HFU 
(0.392mm vs 0.713mm overestimation). 
 
Most studies have used the 20 MHz system for investigating NMSCs although the 
optimal frequency for this examination has not been previously studied. However, it 
is possible that at higher frequency, margins could be more accurately assessed as 
it was previously found that melanoma depths measured with HFU at 75 MHz, but 
not at 20 MHz, correlated significantly with a mean Breslow thickness of 0.4mm. An 
important limitation of HFU is that it merely provides a supporting role with additional 
information about extent and anatomic features of the lesion as the resolution cannot 
distinguish subtypes of skin tumours.(28, 30). 
 
In vivo harmonic generation microscopy (HGM)  
HGM is a relatively new technology, which utilises similar principles to confocal 
microscopy. It achieves a submicron resolution, at a penetration depth up to 270 
micrometer.(37) Its use in non-melanoma skin cancer has recently been investigated 
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in a small case series focusing on pigmented BCC, amongst other pigmented non-
melanoma growths such as melanocytic naevus and seborrheic keratosis (SK). 
Sensitivity of up to 94% (95% CI: 70-99%) and specificity up to 100% (95% CI 87-
100%) were achieved when using their imaging criteria. (37) 
 
Fluorescence 
Laser induced fluorescence utilises non-ionizing radiation delivered via optical fibres 
placed in contact with the skin.(38) Excitation light from the source fibre passes into 
the skin and fluorescence light is emitted back to the surface to be picked up by 
separate optical fibres.(38) Optical measurements are taken and vary according to 
the structural, functional, and biochemical composition of the tissue. (38) The 
fluorescence can be from an endogenous source (autoflourescence) and/or 
exogenous source (photosensitizers). When photosensitizers which accumulate in 
cancer cells are used, it enhances characteristic fluorescence emitted, more clearly 
delineating site of NMSCs, including BCCs.(38, 39) Users require little training, and 
there is little dependency on expertise.(38) Optical properties and fluorophore 
contributions of BCC and normal skin are significantly different from each other and 
shows good histological correlation, which is useful in margin delineation. (38) (39) 
However, its use is limited by intrapatient and intralesional variations.(38) Moreover, 
penetrance of the photosensitizer can be an issue in keratinised lesions such as 
AKs, leading to suboptimal fluorescence. (39) 
 
Ex vivo imaging techniques 
Fluorescence confocal microscopy (FCM) 
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FCM is a new technology which combines florescence staining with RCM to increase 
the diagnostic accuracy.(40-45) In RCM, bright scattering interference typically 
arises from the dermis, making diagnosis difficult. FCM attempts to overcome this by 
using a contrast agent (acridine orange) which stains the nuclei and increases the 
contrast of nucleated cells, weakening the fluorescence from the dermis. In this way 
the contrast between the nuclei and dermis is increased 1000-fold, visualisation of 
small BCCs is possible.(44) 
 
Ex vivo FCM findings in BCC have been described(44) and shows an excellent 
correlation to histologic findings (Cohen’s Kappa statistics = 0.9) (44, 45) In their 
study of 64 BCC cases excised during Mohs surgery, Longo et al. found that the size 
and shape of the tumour islands was a differentiating characteristic between the 
BCC subtypes.(45) Bigger islands corresponded with nodular BCC, smaller and 
round islands with micronodular BCC, and tiny cords were seen in infiltrative 
BCC.(45) Interobserver agreement was more than 0.7 for most of the criteria used to 
diagnose BCC in FCM.(44) This includes the presence of fluorescence, well-
demarcated margin, nuclear crowding, palisading, clefting, nuclear pleomorphism, 
increased enlargement of nuclear to cytoplasmic ratio, and stroma presence.(44) 
The mean time taken using FCM in assessing clearance of margins in excised 
tissues during Mohs compared to standard frozen haematoxylin and eosin-stained 
slides typically used was 10.1 minutes compared to 28.2 minutes (p<0.001). (46) 
The sensitivity and specificity for detecting residual BCC in the surgical margins were 
88% and 99%, respectively. (46)  
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OCT has also been used on an ex vivo basis but results were less ideal than FCM 
and is discussed in detail in appendix 2. 
 
 
Principles of optical coherence tomography 
Compared to the technologies above, OCT provides a compromise between 
penetrance and resolution. It utilises low-coherence interferometry to measure 
optical scattering from beneath the skin surface to produce an image similar to 
ultrasound but with better resolution (28, 47) yet it reaches a deeper layer than RCM, 
sacrificing the cellular resolution RCM offers. Depending on the system, an axial and 
lateral resolution of up to down to 1.5 µm, and a depth of up to 2 mm is achieved in 
general. 
 
Using fibre optics, infrared light is split into a reference beam (probe arm) and a 
probe beam (sample arm), the latter which is placed in contact with the area of 
interest on the skin. (Fig. 2) The probe beam then backscatters, to meet with the 
reference beam. When both beams match within the coherence length of the light, 
interference occurs. Axial resolution (y-axis) therefore is determined by the 
bandwidth and coherence length of the light, whereas the lateral resolution (x-axis) is 
dependent on the focusing objective. 
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 Figure 2: Schematic diagram of OCT system(48) 
 
OCT is used routinely in ophthalmology but of late, applications in dermatology have 
been developed. OCT allows visualisation of the different layers of the skin, including 
the stratum corneum, dermal-epidemal junction, dermal papillae, subcutaneous 
vasculature. Skin adnexal structures such as hair follicles, blood vessels, sebaceous 
glands, can also be seen. (49-52)  
 
The use of OCT has been investigated in a number of skin conditions apart from 
malignancies. This include inflammatory dermatoses, skin infections, vascular 
lesions and hair and nail disorders. (53, 54)  
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Interest in the use of OCT in skin is exponentially rising. This is evident by the 
research publications on the topic in recent decades based on a search of “optical 
coherence tomography” and “skin” on Embase in February 2015. (Fig. 3a). 
 
Figure 3a: Number of publications over time related to OCT and skin. 
 
Optical coherence tomography systems in dermatology 
OCT produces real-time images of skin structures, in vivo, to a maximum depth of 
less than 2mm. The Vivosight 1500 OCT system (Michelson Diagnostics Ltd., 
Orpington, UK) has a lateral and axial optical resolution of 7.5µm and 10µm, 
respectively and a field of view of 6mm x 6mm. It uses a multi-beam frequency 
domain OCT system with a centre wavelength of 1305nm. (Fig. 3b) 
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     High-definition OCT (HD-OCT, Skintell®,   
AgfaHealthCare, Belgium) uses a halogen lamp 
with a Gaussian filter as its light source and has a 
bandwidth centred at 1300 nm. It is a time-domain 
system, which uses dynamic focus tracking through 
synchronisation between the imaging lens system 
and the reference optical system. It takes both 
horizontal and en-face sections, at 3 µm steps, to 
an optimal penetration depth of 450-750 µm. Unlike 
OCT, en-face imaging is performed in real time. 
The field of view in en-face mode is 1.8 x 1.5mm. 
The use of an optical gel is required between the 
probe and the skin.  
 
Full-field OCT (FF-OCT, LightCT, LLTech, Princeton, NJ) is a variation of OCT which 
reconstructs 3D scans of tissues from the original 2D slices captured, working on a 
similar basis as computed tomography, with a resolution up to 1.5 by 1.5 by 1 µm 
and a field acquisition area of approximately 1mm2.(55) The images produced are 
similar to histopathological slides but with a shorter and simpler acquisition process 
since processing of specimen is not required.(55) Current limitations include the 
inability of the machine to accommodate the relatively large specimens, the 
acquisition speed (5 minutes per 1mm2) and the difficulty with diagnosing small foci 
of neoplastic tissue that is otherwise obvious with histopathology.(55) 
 
Figure 3b: Vivosight OCT system 
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A detailed systematic review of the diagnostic accuracy of OCT in the diagnosis and 
management of BCC has been published. (See appendix 2) 
 
A table detailing various OCT systems used in previous study is available in 
appendix 2. 
 
The use of OCT in skin conditions apart from NMSCs is aided by an online atlas 
(http://www.vivosightatlas.com/) maintained by the manufacturer of a conventional 
OCT system. In this atlas, apart from NMSC, there are only images of naevi and 
seborrheic keratosis.  
 
AK is an important clinical confounder of sBCC but differentiation between the two is 
possible on OCT. Features of AK are described below with images adapted from the 
online atlas. (Fig. 4) 
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Figure 4: Top to bottom – H&E of a hypertrophic AK, OCT of corresponding 
hypertrophic AK, H&E of AK with upper dermal infiltrate, OCT of corresponding AK 
with upper dermal infiltrate.  
Legend for Figure 4: A – hyperkeratosis, B – acanothosis or epidermal hyperplasia, 
C – upper dermal inflammatory infiltrate 
 
As the resolution of OCT is not at the cellular level, the histopathologic features of 
parakeratosis, dyskeratosis, cellular atypia of AK cannot be observed 
 
In non-malignant conditions, the use of OCT is preliminary and primarily in the 
exploratory phase. For example, researchers have found that OCT of cutaneous 
lupus erythematousus correlated significantly to histopathology. Histologic features 
of 1) hyperkeratosis, 2) epidermal atrophy, 3) dense upper dermal infiltrate, and 4) 
dilated vessels were observed as 1) thickening and disruption of the entrance signal, 
2) thinner layer below the entrance signal, 3) patchy reduction of reflectivity in the 
upper dermis, and 4) increased signal-free cavities on OCT. (56) The authors felt 
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that although OCT was inadequate to establish a diagnosis, it may be a suitable tool 
for monitoring treatment of cutaneous lupus. Similar results were seen in monitoring 
of erythematotelangiectatic rosacea during topical brimonidine treatment, where 
mean grey value of the OCT imaging corresponding to dermal oedema, could be 
observed to decrease over the treatment period. (57)  
 
The use of OCT in acute allergic contact dermatitis has also been investigated with 
results suggesting a strong correlation with clinical patch test grading, which may 
allow OCT to be used as an objective parameter in grading patch test reaction 
severity. (58) 
 
The histopathologic/OCT correlates of other conditions which are mimickers of sBCC 
cannot be discussed in detail due to the lack of literature. Work is ongoing to 
investigate the use of OCT in differentiating naevi and melanoma and some 
promising results was recently published. (59) 
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Hypothesis and Aim of the project 
Accurate diagnosis of superficial BCC subtype is important, as it is a critical 
determinant to the type of suitable treatment. High cure rates have been 
demonstrated with non-invasive methods, which are also less costly and time 
consuming. Current evidence on the use of OCT in the diagnosis of sBCC is lacking 
(See appendix 2). In particular, large scale, prospective trials have not been 
performed. 
 
The hypotheses of the project are that  
1) OCT can be used to triage lesions into those that can be treated non-
invasively and those that require surgical intervention.  
2) OCT can be used to measure depth of BCC 
 
The aim of the project is to evaluate the sensitivity and specificity of OCT in the 
diagnosis of sBCC and to evaluate its accuracy in depth measurement of BCC. 
 
Materials and methods 
Sample 
The study was performed at the Melanoma Institute Australia (MIA) (Sydney, 
Australia) for 12 months from March 2014 to March 2015. The patient population in 
MIA consists mostly those presenting for skin check, of which a majority have a 
moderate to very high risk of melanoma based on their history. The study was 
conducted according to the Helsinki Declaration and informed consent was obtained 
from all subjects. The study was approved by the ethics committee of St Vincent’s 
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Hospital (SVH 14/025). Neither routine diagnosis nor treatments of the patients were 
affected by the study. 
 
Study procedure 
Recruitment protocol 
1. Adult patients 18 years and older, presenting with lesions suspicious for sBCC 
after dermoscopic examination are recruited consecutively following informed 
consent. 
2. For every suspicious lesion, the clinician’s confidence (after dermoscopic 
examination) that it was a sBCC was recorded.  
3. A clinical and dermoscopic photograph of the identified lesion was taken. 
Clinical images were taken with a Nikon DS300 digital camera and 
dermoscopy images were taken with the same camera attached to a Heine 
Delta 20 dermoscopic attachment (Heine Optotechnik, Herrsching, Germany). 
4. OCT images of lesions and adjacent normal skin were acquired at baseline. 
(See OCT imaging protocol for details) 
5. OCT scanning and interpretations were performed by the same investigator 
throughout the study. OCT interpretation was performed blinded to the 
clinician diagnosing the BCC. For every lesion, OCT confidence of the 
diagnosis was recorded as well as OCT confidence that it was a sBCC.  
6. The lesion then underwent a 2mm punch biopsy for histopathologic 
examination to confirm the diagnosis. If the lesion was confirmed to be sBCC, 
patients were advised to treat with either cryotherapy or imiquimod therapy 
and to present in 6 months for follow up and evaluation. If the lesion was not a 
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sBCC, patients were contacted and treatment was advised as standard 
practices.  
 
OCT imaging protocol 
OCT scans were performed using the Vivosight OCT (Michelson Diagnostics Ltd., 
UK), a Fourier-domain OCT system, which consists of a laser at a centre wavelength 
of 1300nm. A probe is placed directly in contact with the area of skin of interest, 
without the need for an interface agent such as gel or oil. The system has a 
resolution of 7.5 µm laterally and 10 µm vertically. As previously discussed, it 
provides real-time, in vivo, cross sectional images of the lesions. Pre-programed in 
the machine as part of the “en-face” scan, 120 images of 5mm width and 2mm depth 
were captured in sequence to form a series which presents like a video through 
cross sections of the skin. This series of images was exported and analysed using 
ImageJ software. The OCT morphology of lesions at baseline were recorded and 
analysed.  
 
OCT Interpretation 
Analysis was carried out in accordance with the following criteria set out by previous 
studies of OCT morphology of BCC lesions. (35, 47, 49, 60-62) Analyses were 
carried out by a single investigator who was an experienced user in OCT. (HC) 
 
General BCC features 
1. Alteration to the expected dermal-epidermal junction (DEJ) undulations by 
one or more hyporeflective lobules  (Fig 5, 8a/b) 
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 Figure 5: Alteration to the dermal-epidermal junction (DEJ)  
2. Atypically arching and/or increased frequency of prominent vessels in the 
dermis underlying the hyporeflective structures (Fig. 6, 8a/b) 
 
Figure 6: Atypical morphology or increased in frequency of blood vessels  
 
3. Surface contour change in area of hyporeflective structures (Fig. 7, 10b) 
 
Figure 7: Surface contour change   
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Specific BCC features 
Superficial 
1. Hyporeflective ovoid structures with firm attachment to the DEJ 
2. Clefting region focussed or solely visible on the inferior margin (originally 
lower facing) of the hyporeflective structures 
 
Figure 8a: Hyporeflective ovoid structure and clefting region on the inferior margin in 
a superficial BCC on OCT and biopsy. Orange arrows: lateral and superior border of 
the sBCC nests. Note that they are not fully encompassing, as illustrated in Fig. 9a. 
Yellow arrows reflect the inferior border, termed as clefting regions. Between the 
orange and yellow arrows, hyporeflective ovoid structures are seen.  
 
 
Figure 8b: Corresponding sBCC on H&E (10x). Orange and yellow arrows reflect the 
peripheral palisading seen in BCC nests, and also visible on OCT. The BCC nest 
remain firmly attached to the DEJ on the right. Blue arrows show the normal DEJ, 
compared with the disrupted DEJ on the right by the BCC nests. 
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Nodular 
3. Fully encompassing hyporeflective ovoid structure 
 
Figure 9a: Fully encompassing hyporeflective ovoid structure. The yellow arrows 
reflect the inferior border of the BCC nest, and the orange arrows reflect the superior 
border. 
Figure 9b: Corresponding nodular BCC (H&E x4) Large nests of nodular BCC, 
detached from the DEJ. 
Micronodular/Infiltrative 
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4. Small aggregates of hyporeflective ovoid structures; can be connected by 
hyperreflective bands giving a “bunch of grapes” appearance 
 
Figure 10a: Micronodular BCC: Small aggregrates of hyporeflective ovoid structures 
giving a “bunch of grapes” appearance. The inferior border of the BCC nests are 
marked by blue arrows. On the right, small roundish ovoid structures can be seen, 
giving rise to a “bunch of grapes” appearance. The purple arrows mark the superior 
border, which is clearly detached from the DEJ. 
 
Figure 10b: Corresponding micronodular BCC H&E (x4) Small BCC nests, detached 
from the DEJ. Breach in the epidermis is seen and corresponds to the superficial 
contour changes seen on OCT. 
 
 
37 
 
 Interrater reliability 
To assess the interrater reliability of the OCT features and the diagnosis of sBCC, 3 
observers with varying level of OCT experience rated a test set of the lesions. This 
was made up of 44 sBCC (62%), 16 oBCC (23%), 4 AK/SCCIS (6%), 6 other benign 
(9%) and 1 other malignant lesion (1%). This test set comprised of 71 consecutive 
lesions from the first 33 patients recruited. A sample size of 33 subjects achieves 
more than 80% power to detect a true Kappa value of 0.60 in a test of H0: Kappa = 
κ0 vs. H1: Kappa ≠ κ0 when there are 4 categories with frequencies equal to 0.65, 
0.25, 0.06, and 0.04. This power calculation is based on a significance level of 
0.05000. 
 
Two observers were experienced (HC, AM) and one observer was beginner in OCT, 
after completing a training set.(PG) The test set was presented on separate 
occasions to the 2 observers, who scored the images blinded to the histopathologic 
diagnosis. To more closely simulate actual clinical scenario, they had access to the 
age, gender and confidence of the clinician that the BCC was likely to be sBCC, as 
well as access to the clinical and dermoscopic photographs. 
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Statistical analysis 
Statistical analyses were performed using R software (version 3.1.2, Foundation for 
Statistical Computing, Vienna, Austria).  
 
Prior to recruitment, sample size calculation was performed. A total sample size of 
165 (which includes 33 subjects with non-superficial nodular BCC) achieves 99% 
power to detect a change in sensitivity from 0.6 to 0.90 using a one-sided binomial 
test and 100% power to detect a change in specificity from 0.6 to 0.9 using a one-
sided binomial test. 
 
Sensitivity, specificity, positive predictive value, and negative predictive value for 
each OCT diagnosis were calculated compared with histopathologic diagnosis.  
 
Depth measurement on OCT and biopsy were compared as paired samples. To 
obtain the correlation between the two, Pearson correlation coefficient was obtained 
for BCC and various subsets. 
 
Interobserver agreement between the 3 observers on the OCT diagnosis as well as 
on the individual OCT features were estimated using Cohen kappa statistic with 95% 
confidence intervals. 
 
Univariate logistic regression analysis of the OCT features for the diagnosis of 
sBCC, oBCC, nBCC and iBCC were carried out. OCT features were entered as 
dichotomous independent variables into a conditional backward elimination 
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multivariate logistic regression model. Receiver operating characteristic curve and 
area under the curve were plotted and calculated for the models. 
 
Results 
DEMOGRAPHY: A total of 103 consecutive patients with 168 sBCC-like lesions 
clinically suspicious for sBCC were included in the study. Mean number of lesions 
per patient is 1.63. Mean age of the sample was 62.1 +/- 11.9 years (range: 31 to 88 
years) and participants were mostly male (n=63/61%).  Over half of the lesions were 
located on the front of the trunk and back (n=93/55.4%), and the remaining were 
from the upper extremities (31/18.5%), head and neck (23/13.6%), and lower 
extremities (21/12.5%).  
 
PATHOLOGY: Histopathologic diagnoses of the lesions were sBCC (n=87/51.8%) , 
other BCC (oBCC; n=43/25.6%), actinic keratosis (AK) or squamous cell carcinoma 
in-situ (SCCIS) (n=19/11.3%), other benign inflammatory process (n=17/10.1%). 2 
(1.2%) of these were “other malignancies”, which included 1 amelanotic melanoma 
and 1 minimally invasive SCC. Of the oBCC, 29 (67.4% or 11.9% of total) were 
nodular (nBCC) and the remaining were infiltrative (iBCC; 33.6% or 8.3% of total). 
The 17 benign inflammatory lesions were made up of 6 non-specific inflammation, 3 
lichenoid keratosis, 2 scar tissues, 2 solar lentigines, 1 haemangioma, 1 blue 
naevus, 1 chronic dermatitis, and 1 irritated seborrheic keratosis. 
 
DERMOSCOPY: Sensitivity and specificity of sBCC using dermoscopy was 77.0% 
and 23.5% respectively as we included all lesions with a differential diagnosis of 
sBCC even if the clinical confidence in this diagnostic was low. Clinical confidence of 
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sBCC after dermoscopic examination had a significant relationship with the 
pathologic diagnosis of sBCC (p<0.05). A cumulative proportion graph is presented 
to demonstrate the positive correlation between the two. (Fig. 11) 
 
Figure 11: Confidence of the clinician that the lesion is a sBCC after clinical and 
dermoscopic examination plotted against the cumulative proportion of sBCC on 
pathology. 
 
OCT: The absolute frequencies at which the individual features were observed were 
presented in Table 1. Altered DEJ was the most frequently observed finding, 
followed by hyporeflective ovoid structures and atypical vessels. Frequencies of a 
fully encompassing ovoid structure and “bunch of grapes” appearance were the 
lowest, in keeping with the proportion of nBCC and iBCC in the study population. 
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Table 1. Frequencies of OCT criteria according to the histopathologic diagnosis 
Feature sBCC 
(n=87) 
nBCC 
(n=29) 
iBCC 
(n=14) 
AK/Bow
en 
(n=19) 
Other 
inflammat
ory (n=17) 
Other 
malignancy 
(n=2) 
Total 
(n=168) 
Hyporeflective 
ovoid 
structures 
82 
(94.3%) 
27 
(93.1%) 
13 
(92.9%) 
7 
(36.8%) 
7 
(41.2%) 
1 
(50%) 
137 
(81.5%) 
Altered DEJ 84 
(96.6%) 
27 
(93.1) 
13 
(92.9%) 
14 
(73.7%) 
9 
(52.9%) 
2 
(100%) 
149 
(88.7%) 
Clefting 69 
(79.3%) 
10 
(34.5%) 
4 
(28.6%) 
1 
(5.3%) 
4 
(23.5%) 
1 
(50%) 
89 
(53.0%) 
Atypical 
vessels 
58 
(66.7%) 
21 
(72.4%) 
9 
(64.3%) 
12 
(63.2%) 
11 
(64.7%) 
1 
(50%) 
112 
(66.7%) 
Surface 
contour 
change 
45 
(51.3%) 
9 
(31.0%) 
6 
(42.9%) 
6 
(31.6%) 
4 
(23.5%) 
0 70 
(41.7%) 
Fully 
encompassing 
ovoid structure 
4 
(4.6%) 
21 
(72.4%) 
9 
(64.3%) 
1 
(5.3%) 
0 0 35 
(20.8%) 
“Bunch of 
grapes” 
appearance 
4 
(4.6%) 
2 
(6.9%) 
3 
(21.4%) 
0 0 0 9 
(5.3%) 
 
Sensitivity analyses 
The sensitivity, specificity, PPV and NPV were calculated based on a diagnosis 
(sBCC, other BCC, AK/SCCIS, other benign lesion) reached after OCT analysis of 
each lesion and are presented in the table 2 below. OCT is able to diagnose sBCC 
with a high sensitivity of 87% and specificity of 80%. 
Table 2. Sensitivity, specificity, PPV, NPV and diagnostic accuracy of sBCC, oBCC, 
nBCC, iBCC, AK/SCCIS and other benign lesions. 
Condition Sensitivity Specificity PPV NPV Accuracy 
sBCC 
(n=87) 
0.87 0.80 0.83 0.86 0.84 
95% CI( 0.77,0.89) p<0.001 
oBCC 
(n=43) 
0.79 0.93 0.79 0.93 0.89 
95% CI(0.84, 0.94), p<0.001 
nBCC 
(n=29) 
0.72 0.91 0.62 0.94 0.88  
95% CI(0.82,0.92), p=0.06 
iBCC 0.21 0.96 0.33 0.93 0.90  
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(=14) 95% CI(0.85,0.94), p=0.8 
AK/SCCIS 
(n=19) 
0.58 0.98 0.79 0.95 0.93 
95% CI(0.89,0.97), p=0.01 
Other 
benign 
(n=17) 
0.65 0.95 0.58 0.96 0.92 
95% CI(0.86,0.95), p=0.27 
Clinical scenarios based on clinical and OCT confidence 
Assuming 90% confidence to be the threshold for biopsy of a lesion, different clinical 
scenarios were analysed to detect diagnostic accuracy of OCT in these settings.  
When clinician confidence (on clinical and dermoscopy criteria) was 90% or more, 
OCT had a sensitivity and specificity of 96% and 75% respectively for differentiating 
sBCC. Amongst cases with “clinical” confidence of sBCC ≥ 90% (n=41), 39% (n=16) 
were not sBCC on histology. This group consists of oBCC (n=11), benign 
inflammatory lesions (n=4), and an amelanotic melanoma. Amongst these 16 cases 
with high “clinical” confidence of sBCC but proven otherwise on biopsy, OCT 
diagnoses were accurate in 10 cases. Amongst these 10 cases, 8 had ≥ 90% OCT 
confidence. In the amelanotic melanoma case, it was also incorrectly classified on 
OCT but OCT confidence was <90%. (Figure 12) 
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 Fig. 12 Flowchart depicting scenario with high “clinical” confidence of BCC and the 
relationship between final diagnosis and OCT confidence. 
 
When clinician and OCT interpreter were both highly indicative of a diagnosis of 
sBCC (n=35), 4 cases were misdiagnosed (2=other inflammatory, 1=sBCC, 1=mixed 
sBCC and nBCC). In all 4 cases, hyporeflective ovoid structures, disrupted DEJ and 
clefting were seen in the OCT scans, leading to a high diagnostic confidence of 
sBCC. (Fig. 13)  In this situation, 31 cases would have safely avoided a biopsy, 
leading to a reduction of biopsy rates by 76% (31/41) in cases of high clinician 
confidence. 2 BCC cases were misdiagnosed, suggesting an error rate of 
approximately 5%. 
"Clinical "confidence of sBCC >90% (n=41)
OCT accuracy: Sensitivity = 96%, Specificity 
=75%
sBCC (n=25)i.e. 
correctly classified by 
clinician with high 
confidence
OCT confidence of sBCC
<90% (n=2)
sBCC (n=1)
Not sBCC (n=1); 1 nBCC
OCT confidence of sBCC
>90% (n=23)
sBCC (n=23) i.e. 
correctly classified by 
clinician and OCT with 
high confidence
Not sBCC (n=0)
Not sBCC (n=16) i.e. 
incorrectly classified by 
clinician with high 
confidence
OCT confidence of 
diagnosis <90% (n=5)
Correct diagnosis (n=2), 
1=oBCC, 1=other 
inflammatory
Incorrect diagnosis 
(n=3), 1=oBCC, 1=other 
inflammatory, 1 
amelanotic melanoma
OCT confidence of 
diagnosis >90% (n=11)
Correct diagnosis (n=8),  
8=oBCC
Incorrect diagnosis 
(n=3), 1=oBCC, 2=other 
inflammatory
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 Figure 13. Flowchart depicting clinical scenario of high clinical confidence of sBCC 
and the relationship between OCT confidence and subsequent diagnosis 
 
When clinician confidence was not taken into account, and assuming all recruited 
lesions would be biopsied in routine clinical practice, the effect of OCT on biopsy 
rates was analysed. 109 (64.9%) lesions were diagnosed with a high OCT 
confidence of ≥90%. 68 (62.4%) were diagnosed as sBCC on OCT, of which 62 
(91.2%) were histologically-proven sBCC. The remaining comprised of oBCC 
(n=3/4.4%), AK (n=1/1.5%) and other inflammatory conditions (n=4/5.9%). In this 
situation, 68 cases diagnosed as sBCC with high confidence would not be biopsied 
whereas the remaining 41 cases diagnosed as not sBCC with high confidence would 
still be biopsied due to disconcordance between its clinical diagnosis (possible 
sBCC) and OCT diagnosis (unlikely sBCC). This would translate into a biopsy 
reduction rate of 40.1% (68/168), with a 4.4% (3/68) error rate amongst those that 
Clinical confidence of sBCC >90% (n=41)
OCT accuracy: Sensitivity = 96%, Specificity 
=75%
OCT confidence of 
diagnosis <90% (n=6)
Correct diagnosis (n=3), 
1=sBCC, 1=oBCC, 
1=other inflammatory
Incorrect diagnosis 
(n=3), 1=oBCC, 1=other 
inflammatory, 1 
amelanotic melanoma
OCT confidence of 
diagnosis >90% (n=35)
Correct diagnosis (n=31)
23=sBCC, 1=oBCC
Incorrect diagnosis 
(n=4), 1=sBCC, 1=oBCC, 
2=other inflammatory
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were not biopsied. Since all lesions would have been followed up routinely at a 
maximum of 6 month interval, the lesions erroneously diagnosed would be picked up 
at follow up and treated appropriately.  
 
Depth measurement  
Out of 130 histologically-proven BCCs, the depth of 1 sample could not be obtained 
as it was embedded in the en-face orientation. OCT depth measurement was only 
performed on 135 scans diagnosed as BCC on OCT. Consequently, depths of 122 
samples with both histopathological depth and OCT depth were compared. A paired 
scatter plot comparing depth as measured by OCT and depth as measured by 
biopsy is displayed.(Fig. 14) Due to the depth limitation of OCT at 2mm, all OCT 
depths greater than 2mm (visualised as BCC features extending beyond depth of 
OCT limitation) were analysed as 2mm. 
 
Figure 14. Paired scatter plot of biopsy depth against depth on OCT of 122 BCCs 
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 All BCCs with both OCT and pathology measurements (n=122) 
Overall, Pearson’s correlation indicates a moderate relationship between the two 
measurements (r=0.58, p<0.001). Amongst all BCCs where there was a difference 
between OCT and pathology depth measurements, OCT tended to underestimate 
the depth of tumours (visible as points above the line in Figure 14). 
 
The majority of BCCs (n=110, 90.2%) analysed were 1mm or less on pathology. In 
this group, there was a good relationship between OCT and pathology 
measurements of depth (Pearson’s correlation r=0.71, p<0.001) and 88.2% (n=13) 
lies within +/- 0.2mm difference between OCT and pathology. 
Of the 12 BCCs > 1mm, the range of difference between OCT and biopsy depths 
was -2.8mm to 0.6mm.  
 
All sBCC with OCT and pathology measurements (n=82) 
 
Taking 0.4mm as the theoretical threshold for effective topical treatment of sBCC 
(17), sBCC ≤ 0.4mm (n=55) in our data had an excellent Pearson’s correlation 
(r=0.86, p<0.001). In thin sBCCs, OCT tended to overestimate the depth of the 
tumour but all differences in depth obtained between biopsy and OCT were within +/- 
0.1mm. 
 
In sBCC > 0.4mm (n=27), the correlation between OCT and pathology was not 
significant (r=0.31, p=0.06). In this group, OCT tended to underestimate the depth of 
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the tumour. Differences in depth obtained between biopsy and OCT were -1.28mm 
to 1.20mm with majority (89%) of lesions lying within +/- 0.4mm.  
 
Inter-rater agreement 
All OCT diagnosis and measurements were performed by a single observer 
(observer 2), and a subset of 71 consecutive lesions in 33 patients were also 
analysed by an experienced observer (observer 3) and a beginner observer 
(observer 1) to calculate interobserver agreement. The overall agreement of the 
OCT diagnoses between the 3 observers was fair (kappa=0.596). When comparing 
against observer 2, observer 1, who was a beginner, had a fair agreement 
(kappa=0.534) whereas observer 3 had a good agreement (kappa=0.766). 
Interobserver agreement for the OCT parameters varied. Apart from altered DEJ 
which had less than chance agreement (kappa<0), the other parameters had fair to 
substantial agreement with a kappa coefficient of 0.3-0.7. The parameters with the 
highest agreements are “clefting” (k=0.725), “fully encompassing ovoid structure” 
(k=0.694), and “bunch of grapes” appearance (k=0.638). 
 
Univariate analysis 
BCC criteria were analysed in a univariate logistic model for diagnosis of sBCC and 
oBCC separately. Clefting was the strongest positive predictor of sBCC [OR 11.69, 
95% CI (5.79-24.76)] followed by hyporeflective ovoid structure [OR 7.75 95% CI 
(3.02-24.03)] whereas fully encompassing ovoid structure was the most useful 
negative predictor [OR 0.08 95% CI (0.02-0.21)] A diagnostic algorithm to 
differentiate between sBCC and oBCC based on the five most important criteria is 
presented. (Fig. 15) 
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 Table 3. Univariate analysis of BCC criteria for sBCC and oBCC  
Superficial OR (95% CI) P value 
Fully encompassing ovoid 
structure 
0.08 (0.02-0.21) P<0.0001 
Clefting 11.69 (5.79-24.76) P<0.001 
Hyporeflective ovoid 
structures 
7.75 (3.02-24.03) P<0.001 
Altered DEJ 6.89 (2.18-30.54) P=0.003 
Surface contour change 2.40 (1.28-4.56) P=1 
Atypical vessels 1.00 (0.52-1.90) P=1 
“Bunch of grapes” 
appearance 
0.73 (0.18-2.87) P=0.65 
Other BCC   
Fully encompassing ovoid 
structure 
55.38 (19.78-186.75) P<0.0001 
Clefting 0.32 (0.15-0.66) P=0.002 
Hyporeflective ovoid 
structures 
3.85 (1.27-16.73) P=0.03 
“Bunch of grapes” 
appearance 
3.98 (1.01-16.80) P=0.047 
Altered DEJ 1.96 (0.61-8.73) P=0.31 
Surface contour change 0.68 (0.33-1.39) P=0.30 
Atypical vessels 1.21 (0.58-2.62) P=0.62 
Nodular BCC   
Fully encompassing ovoid 
structure 
23.44 (9.11-66.24) P<0.0001 
Infiltrative BCC   
“Bunch of grapes” 
appearance 
6.73 (1.29-29.49) P=0.014 
49 
 
 Figure 15. Flowchart demonstrating a diagnostic algorithm for differentiating between 
sBCC and oBCC on OCT. 
 
Multivariate analysis 
OCT criteria were entered as dichotomous independent variables in a multivariate 
logistic regression model.(Table 5.) Using a conditional backward elimination 
method, we found that the model was not significantly different when hyporeflective 
ovoid structure, clefting underside, and fully encompassing ovoid structure were 
present (AUC 0.846, sensitivity  90.8%, specificity 66.7%) compared to when 
atypical vessels and surface contour changes were also added (AUC 0.877, 
Fully 
encompassing 
ovoid structure; 
55 times more 
likely to be other 
BCC
"Bunch of grapes" 
appearance; 4 
times more likely 
to be other BCC 
Clefting; 12 times 
more likely to be 
sBCC
Hyporeflective 
ovoid structure; 
8 times more 
likely to be 
sBCC
Disrupted 
layering; 7 times 
more likely to be 
sBCC
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sensitivity 90.8%, specificity 68%). Significant criteria in the multivariate analysis 
were also significant in the univariate analysis and the order of importance was also 
similar. The strongest positive predictive criterion was clefting (AUC 0.773, sensitivity 
79.3%, specificity 75.4%). When used to predict other BCC, the model yielded a 
higher accuracy when all five criteria were present (AUC 0.913, sensitivity 83.7%, 
specificity 92.8%) and when the strongest criterion, fully encompassing ovoid 
structure, was present. (AUC 0.829, sensitivity 69.8%, specificity 96%). The receiver 
operating characteristic curves for these five models are presented. (Fig.16) 
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 Figure 16: Receiver operating characteristic curve for models predictive of sBCC and 
oBCC.  
For sBCC diagnosis on pathology, the red, blue and green lines are relevant where - 
- Red=Clefting only (AUC 0.773).  
- Blue=Model with hyporeflective ovoid structure, clefting and fully 
encompassing ovoid structure .(AUC 0.846)  
- Green=Model with all criteria (AUC 0.877).  
For oBCC diagnosis on pathology, the yellow and pink lines are relevant where: - ---
Yellow = fully encompassing ovoid structure only (AUC 0.829),  
- Pink= Model with all criteria (AUC 0.913) 
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Table 5. Multivariate adjusted OCT predictors for superficial BCC and other BCC 
ordered by OR 
Superficial OR (95% CI) P value 
Fully encompassing ovoid 
structure 
0.07 (0.02-0.22) P<0.0001 
Clefting 3.88 (1.53-9.89) P=0.004 
Hyporeflective ovoid 
structures 
5.53 (1.65-20.76) P=0.072 
Altered DEJ 2.40 (0.50-13.97) P=0.290 
Atypical vessels 0.62 (0.24-1.51) P=0.305 
Surface contour change 1.64 (0.70-3.90) P=0.256 
“Bunch of grapes” 
appearance 
0.68 (0.15-3.39) P=0.620 
Other BCC   
Fully encompassing ovoid 
structure 
162 (35.16-1200) P<0.0001 
“Bunch of grapes” 
appearance 
21.59 (4.08-131.82) P=0.0004 
Hyporeflective ovoid 
structures 
3.23 (0.46-28.77) P=0.253 
Altered DEJ 0.21 (0.02-2.11) P=0.175 
Clefting 1.58 (0.40-8.27) P=0.544 
Atypical vessels 2.57 (0.73-11.25) P=0.165 
Surface contour change 1.45 (0.42-5.32) P=0.558 
Results from 2 separate models, 1 for sBCC and 1 for oBCC. Multivariate logistic regression was 
performed using all OCT criteria. Relative risks mutually adjusted for all variables in the model.  
 
 
Discussion 
Diagnostic accuracy of OCT 
In this study, the accuracy of OCT in differentiating sBCC from other clinical 
mimickers of sBCC was assessed. Our results suggest that OCT, in addition to its 
usefulness in diagnosing BCC, has a high diagnostic accuracy in differentiating 
between sBCC and oBCC. In particular, “clefting” feature on OCT is very highly 
predictive of sBCC with a sensitivity 80% and specificity 75%. Of note, this feature 
had an excellent interobserver agreement even for a beginner OCT user (observer 
1). Univariate and multivariate analysis indicate that a fully encompassing ovoid 
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structure is the most powerful negative predictor of sBCC whereas clefting and 
hyporeflective ovoid structure are the most useful positive predictors. When these 3 
criteria were used, there was a sensitivity of 90.8% and specificity of 66.7% for 
diagnosis of sBCC. This is not statistically different from the diagnostic accuracy that 
is possible when all criteria were used and is comparable to results of previous 
studies. (62, 63) (Table 6.)  Additionally, this study also found that a high accuracy 
could be achieved for the diagnosis of nBCC (sensitivity 79%, specificity 93%) and 
iBCC (sensitivity 72%, specificity 91%). The flowchart presented Fig. 15 will be 
useful in practice. 
 
Table 6. Diagnostic accuracy of OCT from previous studies 
Author Study 
characteristics 
BCC 
characteristics 
Results 
Mogensen et 
al. (62) 
105 patients (45 M 
60F, mean age 
69.3)  
Study of NMSCs 
including 64 BCC 
64 BCC location 
and subtype not 
reported 
OCT only: 
Sensitivity 79%-94% and 
specificity 85%-96% for 
all NMSC depending on 
experience. 
 
Ulrich et al. 
(63) 
164 patients, 
characteristics not 
reported 
141 BCC, 
locations and 
subtype not 
reported 
Clinical, dermoscopy and 
OCT combined: 
Sensitivity 96% specificity 
75%, PPV 85%, NPV 
92% 
 
 
Diagnostic accuracy of other non-invasive tools 
Apart from conventional OCT, researchers have also focused on the use of different 
non-invasive tools to diagnose BCC subtypes. (12-14, 64) 
DERMOSCOPY: In our study, we recruited all clinical mimickers of sBCC, including 
lesions with low but possible likelihood of sBCC and excluding only lesions which 
were definitely not sBCC after dermoscopic examination. 58 (35%) lesions had a 
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clinical confidence of ≤50% for sBCC. This accounts for our relatively low sensitivity 
and specificity of dermoscopy at 77% and 26% respectively when compared to 
another study using dermoscopy alone which was able to achieve a higher sensitivity 
and specificity of 81.9% and 81.8%.(13) Importantly, the use of non-polarised 
dermatoscope in this study may have limited our diagnostic accuracy.(65) Our study 
was also performed prospectively and unfortunately we did not employ the proposed 
dermoscopy diagnostic algorithm that was proposed as it has only been published 
recently, after the commencement of our study.(13) 
 
RCM & HD-OCT: Reflectance confocal microscopy (RCM) is an imaging tool similar 
to OCT but having a near-histologic resolution (<2microns lateral resolution) and 
more limited depth penetrance (0.2mm). High definition OCT (HD-OCT) offers a 
compromise between RCM and conventional OCT in terms of resolution (3microns 
lateral resolution) and a depth penetrance of 1mm.  
Features of different BCC subtypes on HD-OCT and RCM have all been 
described.(12-14, 64) The diagnostic accuracies of HD-OCT or RCM in 
differentiating between BCC subtypes have not been investigated although the 
current studies indicate the presence of features, which can potentially aid in this 
differentiation. Further studies will be required to compare the accuracy of HD-OCT 
and RCM with conventional OCT. 
 
Accuracy of OCT in depth measurement 
In our study, in the sBCC  and oBCC subset (n=122), OCT has a moderate 
correlation when measuring depth, tending to underestimate tumour depths (r=0.58, 
p<0.001). This accuracy is highly dependent on the thickness of the tumour. When 
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only BCCs ≤1mm on pathology were analysed, the correlation was good (r=0.71, 
p<0.001).  
 
The same trend was seen in analysis of sBCC. When sBCC ≤ 0.4mm were 
analysed, correlation between OCT and pathology was strong and all differences 
were within +/- 0.1mm.  
 
Two other studies indicated an excellent correlation between OCT depth and biopsy 
depth with mean difference of <0.1mm. (50, 66) However, studies varied in terms of 
BCC subtypes and depths of tumour thickness in the study population. (35, 36) Most 
studies concluded that thinner tumours less than 1 to 1.2mm tended to have better 
correlation.(50, 67)  
 
A study of 127 sBCCs treated with a 6 weeks course of imiquimod, five times a 
week, found that recurrence rate was 58% in tumours >0.40mm, and 0% in those In 
the subset of sBCC ≤0.4mm.(17) The thickness of sBCC is important for determining 
whether imiquimod is an efficacious option or will likely lead to tumour recurrence. 
An excellent OCT and histology correlation for sBCCs ≤0.4mm was demonstrated in 
this study. Since the thickness of BCC tumours cannot be accurately assessed 
through clinical examination alone(68), the use of OCT in determining appropriate 
treatment for sBCC or for predicting recurrence rate after imiquimod therapy based 
on their depths is practical and avoids invasive biopsies.  
 
In this same study, the mean and tumour thickness were 0.30 +/- 0.16 mm and 0.26 
mm (range 0.09 – 0.61 mm). 108/127 tumours were ≤0.04mm. As this study was a 
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retrospective study of sBCC treated with imiquimod, the depths of the study 
population may tend to be smaller. In the present study, most tumours (90.2%) were 
≤ 1mm and the mean depth of sBCCs in this study was 0.65mm (range 0.1 – 
2.3mm). A recent study investigating the thickness of sBCC as a determinant for 
treatment failure with non-invasive therapies also showed that sBCC tended to have 
limited depth with the range from 0.2 – 1.0 mm and a mean of 0.39mm. (69) Since 
most sBCCs tend to be <1mm, the good concordance between OCT and biopsy in 
BCC ≤ 1mm makes it a good tool for measuring depth of sBCC. 
Clinical scenario to determine potential of OCT in avoiding biopsy 
Unique to this study, we considered the confidence of the diagnosis at various 
stages. Although subjective and prone to bias, the lesions were mostly recruited by 
one investigator after clinical assessment and then interpreted by another single 
investigator on OCT. In this way we sought to eliminate interobserver differences.  
 
Assuming all recruited lesions in this study would be biopsied in routine clinical 
practice, and using OCT confidence of <90% as the threshold to biopsy, we would 
have avoided 65 biopsies (39%) at the expense of misdiagnosing 3 other BCC (5%), 
comprising 1 infiltrative, 1 mixed superficial-nodular, and 1 nodular BCC. Of note, in 
our institution, patient review after medical treatment is routinely performed at 6 
months follow up at the latest where the lesion would most likely be biopsied at this 
stage. Evaluation of OCT accuracy in monitoring treatment of sBCC is ongoing. 
 
Using 90% as the cut-off where a diagnosis was certain enough to avoid biopsy, we 
analysed the diagnostic accuracy of the hypothetical scenario where the clinician 
was highly confident of the diagnosis. In this setting, OCT had a nearly perfect 
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sensitivity of 96% although specificity fell to 75% for the diagnosis of sBCC.  
Amongst these cases of high “clinician” confidence, only 61% of lesions were 
correctly confirmed as sBCC on pathology showing the need for diagnosis tool.  If we 
accept that both a clinical and OCT confidence of ≥90% is needed to avoid biopsy, 
we would have correctly diagnosed 31 cases and 1 mixed superficial-nodular BCC 
would have been misdiagnosed. This suggest that OCT can be a useful tool in 
reducing biopsy rates of sBCC. 
 
Interobserver agreement 
Interobserver agreement was dependent on the level of experience of the observer. 
There was good agreement between observers if they had a similar level of 
experience although agreement was still fair when comparing a beginner and an 
experienced observer. This suggests a period of training can increase the accuracy 
of new users of OCT, and this finding is supported by a recent study which attained 
similar results.(70) Slightly poorer interobserver agreement in earlier works likely 
reflect the poorer resolution of the technology at the time. (62) The agreement of the 
features of clefting, fully encompassing ovoid structure and “bunch of grapes” 
appearance were good and this was important because they were the most critical 
predictors of either sBCC or oBCC, as demonstrated in the diagnostic flowchart. 
(Fig.15)  
  
 
 
 
Amelanotic melanoma masquerading as sBCC 
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In our series, we report an amelanotic melanoma case which was diagnosed as 
sBCC with a high confidence “clinically” and was also incorrectly classified on OCT 
as sBCC although OCT confidence was <90%. (Fig. 17)  
 
This is the first case of an amelanotic melanoma on OCT and represents a potential 
important pitfall for the technology. No studies on melanocytic features on 
conventional OCT have been published so far.  
 
Although the amelanotic melanoma presented very similar to sBCC on the OCT, we 
found 2 distinguishing features, illustrated in Fig. 18 and Fig. 19.  
 
1. sBCC tends to develop along the DEJ, in nests. Typically, one can see 
several BCC nests, and they can be connected to one another, as seen in 
Fig. 19. In this amelanotic lentigo maligna melanoma, the nests are much 
smaller and unevenly distributed with minimal connection to one another. (Fig 
18.) 
2. True BCC cell nests can be followed along the sequence of OCT images. In 
Fig 19., we see 3 consecutive OCT images of an sBCC, this particular nest is 
clearly seen in at least 8 consecutive slices of OCT images. In contrast, in Fig. 
18, the melanocytic nest is only seen in the middle image but not clearly 
visible in the image before and after this. Smaller melanocytic nests can be 
seen in this series and similarly, they cannot be appreciated in sequential 
images. 
 
 
59 
 
  
 
Figure 17.: Clinical photograph of a pink macule on the abdomen, dermoscopic 
photograph showing fine telangiectatic vessels. Pathology showed a lentigo maligna 
melanoma with a Breslow thickness of 0.8mm. This was the case of amelanotic 
melanoma in our series misdiagnosed clinically and on OCT but obvious on histology. 
 
60 
 
  
 
Figure 18: Series of 3 consecutive images of the amelanotic melanoma. The middle 
image is nearly diagnostic of sBCC with hyporeflective ovoid structure, altered 
layering and clefting. However, note that the clefts are very small and not clearly 
connected to one another (which can still be early superficial BCC). An important 
distinguishing feature is that these nests are not appreciated in the image before and 
after it. 
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Fig 19: Series of 3 consecutive images of a sBCC. Similarly, the images show 
hyporeflective ovoid structure, altered layering and clefting. In comparison to the 
lentigo maligna melanoma, the BCC nests are larger, and connected to one another. 
Importantly, the nests can be observed over consecutive images. 
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 Limitations 
As previously mentioned, the use of a non-polarised dermatoscope for our study 
may have reduced our clinical accuracy of BCC diagnosis and may also 
subsequently negatively affect the accuracy of BCC diagnosis on both dermoscopy 
and OCT.  As our study was performed in a single centre, the external validity of our 
results is uncertain. As the participants were recruited by a single investigator, who 
was highly skilled in dermosopy, we were able to limit the confounding caused by 
investigators’ varying experience. Moreover, as parts of the study parameters 
involved the clinician’s confidence, which is subjective, we were able to compare this 
result more accurately by recruiting with a single investigator. However, with a single 
investigator recruiting, the study risks selection bias, as all the lesions recruited are 
based on the clinical and dermoscopic expertise of an individual, further limiting its 
external validity. 
 
To minimise invasiveness of an excision biopsy for patients, 2mm punch biopsies 
were used instead of excisional biopsy for the histopathologic diagnosis. This could 
result in sampling error since the OCT field of view is larger than the area of the 
punch biopsy. For example, in one case, a fully encompassing ovoid structure was 
seen suggesting an OCT diagnosis of a nodular BCC. (Fig.18) However, the biopsy 
report showed AK. Although the patient has yet to be reviewed for follow up, it is 
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possible this lesion could be a nodular BCC, which has been biopsied inaccurately. 
 
Figure 18. OCT image of a fully encompassing ovoid structure suggesting a nBCC 
but biopsy results of this lesion showed AK.  
 
Sampling errors could have resulted in an underestimation of the diagnostic 
accuracy of OCT. A new model of OCT has been developed which is now equipped 
with a camera to improve macro-micro correlation and will improve the issue of 
sampling errors. 
 
Similar to other research findings, we do not think that the tumour depth is likely to 
be significantly different when measured using a punch biopsy compared to 
excision.(69) The majority of cases in our cohort are superficial subtype and less 
than 1 mm in depth and discrepancy between biopsy and excision is likely to be 
minimal. 
 
Conclusions and recommendations 
Our study indicates that OCT is a reliable tool for differentiating between sBCC and 
other clinical mimickers. We found that clefting, hyporeflective ovoid structure and 
the absence of a fully encompassing ovoid structure were highly predictive of sBCC. 
Amongst experienced users, OCT has a good diagnostic agreement for the 
presence of these features and the diagnosis of BCC. In our experience, we also find 
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these structures easy to recognise when present and increases our confidence of 
the presence of sBCC. On the contrary, sBCC which do not display these features 
can be difficult to diagnose on OCT. Comparison of OCT and other technologies, 
including the possibility of combination machines is discussed in Appendix 2.  
 
OCT is also a useful tool for depth measurement, particularly for thin tumours under 
0.4mm and acts as a new practical tool not only for determining the need to excise a 
tumour but also for determining the type of topical therapy a sBCC can be treated 
with.  
 
Recommendations for use of OCT in BCC 
OCT is a promising tool in various aspects of BCC diagnosis and management. 
Current studies demonstrate that OCT can be useful in the diagnosis of BCC, 
particularly when used as an adjunct to dermoscopy. It can play a unique role in non-
invasively triaging BCC into superficial (non-surgically managed) cases and other 
subtypes which require proper excision, reducing unnecessary biopsies and 
translating to savings in time and cost. However, users must note that AK is an 
important confounder in BCC diagnosis as misclassification between the two was 
common in one study. 
 
OCT is also valuable in measuring tumour depth of BCCs less than 2mm but 
measurement of depth and margin can be impossible in difficult to reach areas such 
as the periorbit. In-vivo use in MMS to reduce number of stages of surgery has 
shown promising results but ex-vivo use of OCT in MMS is not recommended based 
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on current studies. In monitoring of both surgical and non-surgical treatment of BCC, 
OCT has not yet proven its utility with current studies small in sample sizes with 
varied treatment regimens and outcomes. Additional studies with good 
methodological quality will further implement OCT into daily clinical practice.  
 
Perspectives 
OCT machines on the market are conventional OCT (Vivosight, Michelson 
Diagnostic, UK and Thorlabs, USA), HD-OCT (Skintell, Agfa Healthcare, Belgium), 
FF-OCT (LightCT, LLTech, France) with prices varying from USD$70,000 to 
$150,000. The time to investigate a lesion is less than a minute, similar to high 
frequency ultrasound and a lot better than confocal microscopy (>5min) or 
conventional histology. OCT systems have improved tremendously since their 
inception and efforts are ongoing to continue to balance its physical limitations with 
clinical applicability. For instance, resolution has improved from 10-24µm in the 
earlier machines to 3µm in HD-OCT; a recent model combines dermoscopy camera 
with conventional OCT to facilitate clinical-OCT correlation. Depth penetration is not 
likely to improve to >1.5mm without sacrifice of resolution. 
Amelanotic melanoma may be an important pitfall in this technology. We recommend 
clinicians exercise caution and biopsy lesions, which are suspicious of amelanotic 
melanoma based on history of the patient, evolution of the lesion and clinical and 
dermoscopic findings. Research is ongoing to collect more melanocytic lesions to 
appreciate the features differentiating melanocytic and non-melanocytic, as well as 
benign and malignant. This is conducted in collaboration with a Brazillian centre and 
will undoubtedly increase user confidence when using OCT. 
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 OCT can also be used in situations where clinical confidence of sBCC is: 
- variable as it would reduce biopsy rate by 40% with the risk of misdiagnosing 
other BCC in 3 BCC cases (4%) and 
- high (≥90%) as it would reduce biopsy rate by 76% with the risk of 
misdiagnosing 2 BCC cases (5%) 
 
If we accept that these patients will have medical treatment and will need follow up to 
determine the efficiency of these, it can increase the diagnostic accuracy and 
confidence of clinicians. Reducing biopsies minimises pain and cost to patient. It 
eliminates the need for a repeat appointment to decide management and also 
represents huge cost savings to the health system. To investigate the usefulness of 
OCT in assessing treatment efficacy and tumour recurrence, the study will continue 
to follow up all sBCC cases post cryotherapy or imiquimod therapy.  
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